Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Khiron Life Sciences Corp.
  6. News
  7. Summary
    KHRN   CA49374L3065

KHIRON LIFE SCIENCES CORP.

(KHRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Khiron Life Sciences : provides European management updates

06/14/2021 | 05:37pm EDT

TORONTO, June 14, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the appointment of Franziska Katterbach as President, Khiron Europe to replace Tejinder Virk, who has resigned from the Company.

Franziska Katterbach Appointed President of Khiron Europe
Since her appointment in October 2019 to the role of Managing Director and Chief Legal Counsel, Khiron Europe, Ms. Katterbach has been at the forefront of Khiron's European operations. Franziska's promotion to the position of President aligns with the Company's commitment to diversity and inclusion throughout the organization, including at the Executive level.

"I would like to congratulate Franziska on her appointment, which comes at a very exciting time for our European team. Since joining Khiron, Franziska has been a driving force behind our European operations. Her regulatory expertise, strong leadership skills and exceptional day-to-day management of operations have allowed us to develop a differentiated, asset-light platform. Most recently, the European team launched another new product into the German market while more than tripling shipment volumes, demonstrating strong execution in Europe's largest market," comments Alvaro Torres, CEO and Director.

Franziska Katterbach, President, Khiron Europe, comments, "I am a great believer in Europe's medical cannabis market and am honoured to lead our world-class team as we expand patient access, along with our market presence, in Germany and the UK. On behalf of the Company, I would like to thank Tejinder for his many contributions to our European operations and wish him well in his future endeavors."

Mr. Virk´s resignation will result in the forfeiture of 2.2 million stock options and 600,000 restricted share units previously awarded.

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/khiron-provides-european-management-updates-301311923.html

SOURCE Khiron Life Sciences Corp.

© Canada Newswire, source Canada Newswire English

All news about KHIRON LIFE SCIENCES CORP.
09/13KHIRON LIFE SCIENCES : Renews Normal Course Issuer Bid
MT
09/09KHIRON LIFE SCIENCES : Announces Intention to Renew Normal Course Issuer Bid
MT
09/09Khiron Life Sciences Corp. announces an Equity Buyback for 8,955,893 shares, representi..
CI
09/09Khiron Life Sciences Corp. authorizes a Buyback Plan.
CI
08/31KHIRON LIFE SCIENCES : Registers First Medical Cannabis Products in Peru
MT
08/31KHIRON LIFE SCIENCES : Registers its First Two Medical Cannabis Products in Peru, Availabl..
PR
08/31Khiron Registers its First Two Medical Cannabis Products in Peru
CI
08/23KHIRON LIFE SCIENCES : Books Q2 Loss of C$0.03 per Share, Expects Medical Cannabis Revenue..
MT
08/23Khiron Life Sciences Corp. Reports Earnings Results for the Second Quarter Ended June 3..
CI
08/11KHIRON LIFE SCIENCES CORP. : Invitation to the Q3 Virtual Investor Summit
NE
More news
Financials
Sales 2021 13,0 M 10,3 M 10,3 M
Net income 2021 -22,2 M -17,5 M -17,5 M
Net Debt 2021 15,0 M 11,8 M 11,8 M
P/E ratio 2021 -1,40x
Yield 2021 -
Capitalization 50,2 M 39,5 M 39,6 M
EV / Sales 2021 5,01x
EV / Sales 2022 2,23x
Nbr of Employees -
Free-Float 94,7%
Chart KHIRON LIFE SCIENCES CORP.
Duration : Period :
Khiron Life Sciences Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KHIRON LIFE SCIENCES CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,28 CAD
Average target price 0,85 CAD
Spread / Average Target 204%
EPS Revisions
Managers and Directors
┴lvaro F. Torres Chief Executive Officer & Director
Joel Friedman Chief Financial Officer
Chris Naprawa Chairman
Jairo Espinoza Vice President-Medical Affairs
Manuel Buendia Vice President-Operations
Sector and Competitors